Read about Orkambi, which combines ivacaftor with lumacaftor, and find out how the drug could help to treat people with cystic fibrosis (CF).
What is Orkambi?
Orkambi is made up of ivacaftor and lumacaftor. The treatment has been shown to be effective in people with CF with two copies of the F508del mutation, which around 50% of people with CF in the UK have.
What effect does Orkambi have?
96-week data shows that Orkambi can slow decline in lung function – the main cause of death among people with cystic fibrosis – by 42%.
Is Orkambi available in the UK?
Orkambi is available for use in the UK for people with CF over the age of two with two copies of the F508del mutation.
Managed access agreements to make Orkambi available on the NHS have now been agreed in England, Scotland, Wales and Northern Ireland. To find out whether you or your child might be eligible for a precision medicine, please speak to your CF team.
The UK CF Registry, which is maintained by the Trust, is playing a vital role in supporting these agreements by collecting data on the health outcomes of individuals taking Orkambi and other recently licensed drugs.
Stay up to date with our campaign for access to life-saving drugs by signing up to our campaign newsletter.
Fighting for life-saving drugs
Find out more about our campaign to ensure that people with CF across the UK can have access to innovative precision medicines.
Join a campaign
Sign up to our campaigning mailing list and we'll keep you up to date on the CF campaigns you're interested in and the campaign actions relevant to you.
Find out what's been happening in our campaign for life-saving drugs since it began in 2015.